Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study
Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to internatio...
Saved in:
| Published in: | The lancet oncology Vol. 20; no. 1; pp. 74 - 87 |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Elsevier Ltd
01.01.2019
Elsevier Limited Lancet Pub. Group |
| Subjects: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival.
In this population-based study, we collected data from all patients aged 18–99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics.
We extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England (63·9%, 95% CI 63·5–64·3) and Denmark (65·7%, 64·7–66·8) than in Norway (69·5%, 68·4–70·5) and Sweden (72·1%, 71·2–73·0). Rectal cancer survival was lower in England (69·7%, 69·1–70·3) than in the other three countries (Denmark 72·5%, 71·1–74·0; Sweden 74·1%, 72·7–75·4; and Norway 75·0%, 73·1–76·8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0–87·6; stage III rectal cancer 75·5%, 74·2–76·7; and stage IV colon cancer 20·5%, 19·9–21·1) than in Norway (94·1%, 91·5–96·0; 83·4%, 80·1–86·1; and 33·0%, 31·0–35·1) and Sweden (92·9%, 90·8–94·6; 80·6%, 78·2–82·7; and 23·7%, 22·0–25·3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91·2%, 88·8–93·1; and stage IV colon cancer 23·5%, 21·9–25·1). The total proportion of patients treated with resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70·3% to 88·2%).
Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival.
Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348). |
|---|---|
| AbstractList | Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival.
In this population-based study, we collected data from all patients aged 18-99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics.
We extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England (63·9%, 95% CI 63·5-64·3) and Denmark (65·7%, 64·7-66·8) than in Norway (69·5%, 68·4-70·5) and Sweden (72·1%, 71·2-73·0). Rectal cancer survival was lower in England (69·7%, 69·1-70·3) than in the other three countries (Denmark 72·5%, 71·1-74·0; Sweden 74·1%, 72·7-75·4; and Norway 75·0%, 73·1-76·8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0-87·6; stage III rectal cancer 75·5%, 74·2-76·7; and stage IV colon cancer 20·5%, 19·9-21·1) than in Norway (94·1%, 91·5-96·0; 83·4%, 80·1-86·1; and 33·0%, 31·0-35·1) and Sweden (92·9%, 90·8-94·6; 80·6%, 78·2-82·7; and 23·7%, 22·0-25·3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91·2%, 88·8-93·1; and stage IV colon cancer 23·5%, 21·9-25·1). The total proportion of patients treated with resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70·3% to 88·2%).
Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival.
Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348). Summary Background Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival. Methods In this population-based study, we collected data from all patients aged 18–99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics. Findings We extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England (63·9%, 95% CI 63·5–64·3) and Denmark (65·7%, 64·7–66·8) than in Norway (69·5%, 68·4–70·5) and Sweden (72·1%, 71·2–73·0). Rectal cancer survival was lower in England (69·7%, 69·1–70·3) than in the other three countries (Denmark 72·5%, 71·1–74·0; Sweden 74·1%, 72·7–75·4; and Norway 75·0%, 73·1–76·8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0–87·6; stage III rectal cancer 75·5%, 74·2–76·7; and stage IV colon cancer 20·5%, 19·9–21·1) than in Norway (94·1%, 91·5–96·0; 83·4%, 80·1–86·1; and 33·0%, 31·0–35·1) and Sweden (92·9%, 90·8–94·6; 80·6%, 78·2–82·7; and 23·7%, 22·0–25·3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91·2%, 88·8–93·1; and stage IV colon cancer 23·5%, 21·9–25·1). The total proportion of patients treated with resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70·3% to 88·2%). Interpretation Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival. Funding Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348). Background Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival. Methods In this population-based study, we collected data from all patients aged 18-99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics. Findings We extracted registry data for 139457 adult patients with invasive colorectal adenocarcinoma: 12958 patients in Denmark, 97466 in England, 11450 in Norway, and 17583 in Sweden. 3-year colon cancer survival was lower in England (63.9%, 95% CI 63.5-64.3) and Denmark (65.7%, 64.7-66.8) than in Norway (69.5%, 68.4-70.5) and Sweden (72.1%, 71.2-73.0). Rectal cancer survival was lower in England (69.7%, 69.1-70.3) than in the other three countries (Denmark 72.5%, 71.1-74.0; Sweden 74.1%, 72.7-75.4; and Norway 75.0%, 73.1-76.8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86.4%, 95% CI 85.0-87.6; stage III rectal cancer 75.5%, 74.2-76.7; and stage IV colon cancer 20.5%, 19.9-21.1) than in Norway (94.1%, 91.5-96.0; 83.4%, 80.1-86.1; and 33.0%, 31.0-35.1) and Sweden (92.9%, 90.8-94.6; 80.6%, 78.2-82.7; and 23.7%, 22.0-25.3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91.2%, 88.8-93.1; and stage IV colon cancer 23.5%, 21.9-25.1). The total proportion of patients treated with resectional surgery ranged from 47803 (68.4%) of 69867 patients in England to 9582 (81.3%) of 11786 in Sweden for colon cancer, and from 16544 (59.9%) of 27599 in England to 4106 (70.8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19078 [59.7%] of 31946 patients in England to 4429 [80.9%] of 5474 in Sweden; rectal cancer 4663 [45.7%] of 10195 in England to 1342 [61.9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70.3% to 88.2%). Interpretation Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival. Copyright 2018 (C) The Author(s). Published by Elsevier Ltd. Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival.BACKGROUNDSurvival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival.In this population-based study, we collected data from all patients aged 18-99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics.METHODSIn this population-based study, we collected data from all patients aged 18-99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics.We extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England (63·9%, 95% CI 63·5-64·3) and Denmark (65·7%, 64·7-66·8) than in Norway (69·5%, 68·4-70·5) and Sweden (72·1%, 71·2-73·0). Rectal cancer survival was lower in England (69·7%, 69·1-70·3) than in the other three countries (Denmark 72·5%, 71·1-74·0; Sweden 74·1%, 72·7-75·4; and Norway 75·0%, 73·1-76·8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0-87·6; stage III rectal cancer 75·5%, 74·2-76·7; and stage IV colon cancer 20·5%, 19·9-21·1) than in Norway (94·1%, 91·5-96·0; 83·4%, 80·1-86·1; and 33·0%, 31·0-35·1) and Sweden (92·9%, 90·8-94·6; 80·6%, 78·2-82·7; and 23·7%, 22·0-25·3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91·2%, 88·8-93·1; and stage IV colon cancer 23·5%, 21·9-25·1). The total proportion of patients treated with resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70·3% to 88·2%).FINDINGSWe extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England (63·9%, 95% CI 63·5-64·3) and Denmark (65·7%, 64·7-66·8) than in Norway (69·5%, 68·4-70·5) and Sweden (72·1%, 71·2-73·0). Rectal cancer survival was lower in England (69·7%, 69·1-70·3) than in the other three countries (Denmark 72·5%, 71·1-74·0; Sweden 74·1%, 72·7-75·4; and Norway 75·0%, 73·1-76·8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0-87·6; stage III rectal cancer 75·5%, 74·2-76·7; and stage IV colon cancer 20·5%, 19·9-21·1) than in Norway (94·1%, 91·5-96·0; 83·4%, 80·1-86·1; and 33·0%, 31·0-35·1) and Sweden (92·9%, 90·8-94·6; 80·6%, 78·2-82·7; and 23·7%, 22·0-25·3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91·2%, 88·8-93·1; and stage IV colon cancer 23·5%, 21·9-25·1). The total proportion of patients treated with resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70·3% to 88·2%).Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival.INTERPRETATIONSurvival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival.Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348).FUNDINGEarly Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348). SummaryBackgroundSurvival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival. MethodsIn this population-based study, we collected data from all patients aged 18–99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics. FindingsWe extracted registry data for 139 457 adult patients with invasive colorectal adenocarcinoma: 12 958 patients in Denmark, 97 466 in England, 11 450 in Norway, and 17 583 in Sweden. 3-year colon cancer survival was lower in England (63·9%, 95% CI 63·5–64·3) and Denmark (65·7%, 64·7–66·8) than in Norway (69·5%, 68·4–70·5) and Sweden (72·1%, 71·2–73·0). Rectal cancer survival was lower in England (69·7%, 69·1–70·3) than in the other three countries (Denmark 72·5%, 71·1–74·0; Sweden 74·1%, 72·7–75·4; and Norway 75·0%, 73·1–76·8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86·4%, 95% CI 85·0–87·6; stage III rectal cancer 75·5%, 74·2–76·7; and stage IV colon cancer 20·5%, 19·9–21·1) than in Norway (94·1%, 91·5–96·0; 83·4%, 80·1–86·1; and 33·0%, 31·0–35·1) and Sweden (92·9%, 90·8–94·6; 80·6%, 78·2–82·7; and 23·7%, 22·0–25·3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91·2%, 88·8–93·1; and stage IV colon cancer 23·5%, 21·9–25·1). The total proportion of patients treated with resectional surgery ranged from 47 803 (68·4%) of 69 867 patients in England to 9582 (81·3%) of 11 786 in Sweden for colon cancer, and from 16 544 (59·9%) of 27 599 in England to 4106 (70·8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19 078 [59·7%] of 31 946 patients in England to 4429 [80·9%] of 5474 in Sweden; rectal cancer 4663 [45·7%] of 10 195 in England to 1342 [61·9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70·3% to 88·2%). InterpretationSurvival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival. FundingEarly Diagnosis Policy Research Grant from Cancer Research UK ( C7923/A18348). Background Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national colorectal cancer registries to assess whether differences in the proportion of patients receiving resectional surgery could contribute to international differences in colorectal cancer survival. Methods In this population-based study, we collected data from all patients aged 18-99 years diagnosed with primary, invasive, colorectal adenocarcinoma from Jan 1, 2010, to Dec 31, 2012, in Denmark, England, Norway, and Sweden, from national colorectal cancer registries. We estimated age-standardised net survival using multivariable modelling, and we compared the proportion of patients receiving resectional surgery by stage and age. We used logistic regression to predict the resectional surgery status patients would have had if they had been treated as in the best performing country, given their individual characteristics. Findings We extracted registry data for 139457 adult patients with invasive colorectal adenocarcinoma: 12958 patients in Denmark, 97466 in England, 11450 in Norway, and 17583 in Sweden. 3-year colon cancer survival was lower in England (63.9%, 95% CI 63.5-64.3) and Denmark (65.7%, 64.7-66.8) than in Norway (69.5%, 68.4-70.5) and Sweden (72.1%, 71.2-73.0). Rectal cancer survival was lower in England (69.7%, 69.1-70.3) than in the other three countries (Denmark 72.5%, 71.1-74.0; Sweden 74.1%, 72.7-75.4; and Norway 75.0%, 73.1-76.8). We found no significant differences in survival for patients with stage I disease in any of the four countries. 3-year survival after stage II or III rectal cancer and stage IV colon cancer was consistently lower in England (stage II rectal cancer 86.4%, 95% CI 85.0-87.6; stage III rectal cancer 75.5%, 74.2-76.7; and stage IV colon cancer 20.5%, 19.9-21.1) than in Norway (94.1%, 91.5-96.0; 83.4%, 80.1-86.1; and 33.0%, 31.0-35.1) and Sweden (92.9%, 90.8-94.6; 80.6%, 78.2-82.7; and 23.7%, 22.0-25.3). 3-year survival after stage II rectal cancer and stage IV colon cancer was also lower in England than in Denmark (stage II rectal cancer 91.2%, 88.8-93.1; and stage IV colon cancer 23.5%, 21.9-25.1). The total proportion of patients treated with resectional surgery ranged from 47803 (68.4%) of 69867 patients in England to 9582 (81.3%) of 11786 in Sweden for colon cancer, and from 16544 (59.9%) of 27599 in England to 4106 (70.8%) of 5797 in Sweden for rectal cancer. This range was widest for patients older than 75 years (colon cancer 19078 [59.7%] of 31946 patients in England to 4429 [80.9%] of 5474 in Sweden; rectal cancer 4663 [45.7%] of 10195 in England to 1342 [61.9%] of 2169 in Sweden), and the proportion of patients treated with resectional surgery was consistently lowest in England. The age gradient of the decline in the proportion of patients treated with resectional surgery was steeper in England than in the other three countries in all stage categories. In the hypothetical scenario where all patients were treated as in Sweden, given their age, sex, and disease stage, the largest increase in resectional surgery would be for patients with stage III rectal cancer in England (increasing from 70.3% to 88.2%). Interpretation Survival from colon cancer and rectal cancer in England and colon cancer in Denmark was lower than in Norway and Sweden. Survival paralleled the relative provision of resectional surgery in these countries. Differences in patient selection for surgery, especially in patients older than 75 years or individuals with advanced disease, might partly explain these differences in international colorectal cancer survival. |
| Author | Glimelius, Bengt Di Girolamo, Chiara Maringe, Camille Lundqvist, Kristina Guren, Marianne Grønlie Coleman, Michel P Iversen, Lene Hjerrild Morris, Melanie Schnell, Edrun Andrea Benitez Majano, Sara Rachet, Bernard Christensen, Jane Walters, Sarah |
| AuthorAffiliation | b Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK g Department of Surgery, Aarhus University Hospital, and Danish Colorectal Cancer Group, Aarhus, Denmark e Department of Oncology and KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norwa i Department of Radiation Sciences, Oncology, Umeå University, and Regionalt Cancercentrum Norr, Umeå, Sweden d Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy h Data Delivery Unit, Cancer Registry of Norway, Oslo, Norway j Cancer Control, Documentation and Quality, Danish Cancer Society, Copenhagen, Denmark a Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK c Department of Population Health, London School of Hygiene & Tropical Medicine, London, UK f Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden |
| AuthorAffiliation_xml | – name: b Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK – name: j Cancer Control, Documentation and Quality, Danish Cancer Society, Copenhagen, Denmark – name: a Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – name: g Department of Surgery, Aarhus University Hospital, and Danish Colorectal Cancer Group, Aarhus, Denmark – name: d Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy – name: e Department of Oncology and KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norwa – name: c Department of Population Health, London School of Hygiene & Tropical Medicine, London, UK – name: h Data Delivery Unit, Cancer Registry of Norway, Oslo, Norway – name: i Department of Radiation Sciences, Oncology, Umeå University, and Regionalt Cancercentrum Norr, Umeå, Sweden – name: f Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden |
| Author_xml | – sequence: 1 givenname: Sara surname: Benitez Majano fullname: Benitez Majano, Sara email: sara.benitezmajano@lshtm.ac.uk organization: Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 2 givenname: Chiara surname: Di Girolamo fullname: Di Girolamo, Chiara organization: Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 3 givenname: Bernard surname: Rachet fullname: Rachet, Bernard organization: Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 4 givenname: Camille surname: Maringe fullname: Maringe, Camille organization: Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 5 givenname: Marianne Grønlie surname: Guren fullname: Guren, Marianne Grønlie organization: Department of Oncology and KG Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norwa – sequence: 6 givenname: Bengt surname: Glimelius fullname: Glimelius, Bengt organization: Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden – sequence: 7 givenname: Lene Hjerrild surname: Iversen fullname: Iversen, Lene Hjerrild organization: Department of Surgery, Aarhus University Hospital, and Danish Colorectal Cancer Group, Aarhus, Denmark – sequence: 8 givenname: Edrun Andrea surname: Schnell fullname: Schnell, Edrun Andrea organization: Data Delivery Unit, Cancer Registry of Norway, Oslo, Norway – sequence: 9 givenname: Kristina surname: Lundqvist fullname: Lundqvist, Kristina organization: Department of Radiation Sciences, Oncology, Umeå University, and Regionalt Cancercentrum Norr, Umeå, Sweden – sequence: 10 givenname: Jane surname: Christensen fullname: Christensen, Jane organization: Cancer Control, Documentation and Quality, Danish Cancer Society, Copenhagen, Denmark – sequence: 11 givenname: Melanie surname: Morris fullname: Morris, Melanie organization: Department of Health Services Research and Policy, London School of Hygiene & Tropical Medicine, London, UK – sequence: 12 givenname: Michel P surname: Coleman fullname: Coleman, Michel P organization: Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK – sequence: 13 givenname: Sarah surname: Walters fullname: Walters, Sarah organization: Department of Population Health, London School of Hygiene & Tropical Medicine, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30545752$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-155643$$DView record from Swedish Publication Index (Umeå universitet) https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-374440$$DView record from Swedish Publication Index (Uppsala universitet) |
| BookMark | eNqNkl1v0zAUhiM0xLbCTwBF4mZIDdiJvzLE0LSND2mCiwK3luucFm-JXeyko_8eJxkVq4S2qzj2cx4dH7-HyZ51FpLkOUavMcLszQwTjrIcEXqExasCMcIy9ig5iNsko0SIvWE9IvvJYQhXCGGOEX2S7BeIEsppfpD8nnV-abSq09aDahuwbapslYbOr806bi-8a1LtaudBt_FfK6vBp8am52Ab5a-n6YVd1rFmmn5x_kZtpoNgdgMV2ONUpSu36mrVGmezuQoQ3W1XbZ4mjxeqDvDs9jtJvn-4-Hb2Kbv8-vHz2ellpjmhbYYrLDguAZU5pUxgAjliwOcLTvg8nimuKV0UmildlCKnICrGgBTx0nguSl5MkunoDTew6uZy5U3seiOdMvLc_DiVzi9l18mCE0JQxLMH4E0ncWyHFJE_GfkIN1DpOD-v6jtld0-s-SmXbi1ZgUWe51FwdCvw7lcHoZWNCRrqOFFwXZA5ppxxVNIyoi930CvXeRunFymWl4Iy1lMv_u1o28rfN48AHQHtXQgeFlsEI9lnSw7Zkn1wJBZyyFbsd5K83anTph3eNV7M1PdWvx-rIT722oCXQRuIWapMnyxZOXOv4WTHoGtj--xewwbCdhZYhlyiUdI7sBgMveDd_wUPaOAPKs0QUw |
| CitedBy_id | crossref_primary_10_1016_j_ejso_2020_03_002 crossref_primary_10_1002_cjp2_303 crossref_primary_10_1007_s11605_021_05192_x crossref_primary_10_1080_0284186X_2020_1725111 crossref_primary_10_1177_17588359211020547 crossref_primary_10_1080_00015458_2019_1642598 crossref_primary_10_1016_j_ejso_2020_02_040 crossref_primary_10_1002_ijc_33326 crossref_primary_10_1038_s41416_021_01655_9 crossref_primary_10_1016_j_ctarc_2025_100866 crossref_primary_10_1016_j_ctarc_2024_100810 crossref_primary_10_34922_AE_2025_38_1_002 crossref_primary_10_1080_0284186X_2023_2197121 crossref_primary_10_5604_01_3001_0054_8322 crossref_primary_10_1007_s00464_023_10300_w crossref_primary_10_1016_j_canep_2020_101743 crossref_primary_10_3390_cancers16030631 crossref_primary_10_1111_codi_15910 crossref_primary_10_1007_s00432_023_05070_w crossref_primary_10_3389_fonc_2023_1109978 crossref_primary_10_1111_codi_15794 crossref_primary_10_3389_fchem_2021_672917 crossref_primary_10_1016_j_ijsu_2022_106628 crossref_primary_10_1136_jech_2021_217043 crossref_primary_10_2147_CMAR_S354360 crossref_primary_10_1016_j_jgo_2021_04_003 crossref_primary_10_1038_s41416_020_01034_w crossref_primary_10_1002_bjs5_50237 crossref_primary_10_1016_j_clon_2019_12_008 crossref_primary_10_1016_j_ejso_2020_09_024 crossref_primary_10_1016_j_clcc_2019_07_003 crossref_primary_10_1002_ijc_34463 crossref_primary_10_1038_s41575_024_00932_1 crossref_primary_10_1159_000500730 crossref_primary_10_4251_wjgo_v14_i1_242 crossref_primary_10_1002_cnr2_1869 crossref_primary_10_1038_s41416_022_01720_x crossref_primary_10_1093_ageing_afaf025 crossref_primary_10_1007_s00423_021_02143_7 crossref_primary_10_1093_bjsopen_zrac098 crossref_primary_10_1186_s12885_019_5475_x crossref_primary_10_1016_j_canlet_2021_09_034 crossref_primary_10_1097_CEJ_0000000000000836 crossref_primary_10_3892_ol_2019_11203 crossref_primary_10_1186_s12885_023_11329_9 crossref_primary_10_1016_j_jgo_2022_04_011 crossref_primary_10_1136_gutjnl_2020_320625 crossref_primary_10_1038_s41379_020_0587_z crossref_primary_10_1038_s41391_021_00439_9 crossref_primary_10_1016_j_suronc_2019_12_004 crossref_primary_10_1002_1878_0261_12819 crossref_primary_10_3390_cancers14102368 crossref_primary_10_3390_jpm10040168 crossref_primary_10_1007_s12029_022_00899_9 crossref_primary_10_1136_bmjopen_2023_078284 crossref_primary_10_1186_s12885_021_08415_1 crossref_primary_10_4103_jrms_JRMS_430_20 crossref_primary_10_1007_s10924_021_02290_4 crossref_primary_10_1016_j_ejca_2022_05_032 crossref_primary_10_1016_j_surg_2021_08_002 crossref_primary_10_3390_jcm12155041 crossref_primary_10_1080_00365521_2020_1720280 crossref_primary_10_1016_j_ejso_2019_10_010 crossref_primary_10_1093_ageing_afae105 crossref_primary_10_1038_s41598_024_54943_8 crossref_primary_10_3390_cancers16020366 crossref_primary_10_1080_0284186X_2023_2257376 crossref_primary_10_1186_s12885_022_09384_9 crossref_primary_10_1016_j_ejon_2019_101679 crossref_primary_10_1016_j_ejso_2019_06_012 crossref_primary_10_1002_bjs5_50254 crossref_primary_10_1038_s41416_025_02949_y crossref_primary_10_1016_j_ejca_2022_08_015 crossref_primary_10_3390_cancers13215520 crossref_primary_10_1016_j_jgo_2021_11_004 crossref_primary_10_1093_bjsopen_zrae091 crossref_primary_10_1016_j_canep_2023_102363 crossref_primary_10_1080_0284186X_2021_1896033 crossref_primary_10_1007_s00520_025_09496_5 crossref_primary_10_1186_s12885_022_10058_9 crossref_primary_10_3390_cancers12113308 crossref_primary_10_1016_j_ejca_2019_10_022 crossref_primary_10_1038_s41598_023_38853_9 crossref_primary_10_1016_j_ctrv_2022_102490 crossref_primary_10_1097_DCR_0000000000001686 crossref_primary_10_1186_s12876_021_01692_x crossref_primary_10_1186_s12957_020_01895_8 |
| Cites_doi | 10.1093/annonc/mdw235 10.1136/gutjnl-2014-309086 10.1038/bjc.2016.177 10.1007/s00384-014-1959-y 10.3109/0284186X.2015.1034876 10.1093/annonc/mdu253 10.2147/CLEP.S99481 10.1038/bjc.2015.265 10.1016/j.ejca.2004.07.002 10.1093/annonc/mdt197 10.1136/gut.2010.229575 10.1016/j.ijsu.2016.12.123 10.3109/0284186X.2015.1131331 10.1111/codi.13060 10.1177/1536867X0700700103 10.1016/j.clon.2016.02.002 10.1002/bjs.10503 10.1016/S1470-2045(14)70105-6 10.1016/j.healthpol.2011.11.001 10.1016/j.radonc.2017.04.012 10.1016/S0140-6736(14)61347-7 10.4251/wjgo.v7.i12.383 10.1245/s10434-014-3596-7 10.1016/j.radonc.2016.11.010 10.1136/gut.47.4.533 10.1016/j.canep.2014.02.013 10.1200/JCO.2002.20.2.494 10.1016/S0895-4356(96)00236-3 10.1053/j.gastro.2018.03.062 10.1016/j.ejso.2012.01.005 10.1016/S0140-6736(10)62231-3 10.1016/S0895-4356(97)00280-1 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q 10.1136/bmj.k1581 10.1002/bjs.10536 10.1080/0284186X.2018.1529425 10.1016/S1470-2045(14)71199-4 10.1177/1536867X1601600410 10.1007/s00464-016-4819-8 10.1016/j.ejca.2013.06.048 10.1111/j.1463-1318.2008.01735.x 10.1093/annonc/mds278 10.1016/S0140-6736(17)33326-3 10.1038/sj.bjc.6605402 10.3109/0284186X.2013.764008 |
| ContentType | Journal Article |
| Copyright | 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Jan 2019 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 |
| Copyright_xml | – notice: 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license – notice: Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Jan 2019 – notice: 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license 2019 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC ACNBI DF2 |
| DOI | 10.1016/S1470-2045(18)30646-6 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Umeå universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Umeå universitet SwePub Articles full text SWEPUB Uppsala universitet full text SWEPUB Uppsala universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 87 |
| ExternalDocumentID | oai_DiVA_org_uu_374440 oai_DiVA_org_umu_155643 PMC6318222 30545752 10_1016_S1470_2045_18_30646_6 S1470204518306466 1_s2_0_S1470204518306466 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Comparative Study |
| GeographicLocations | England Scandinavian and Nordic Countries Denmark Sweden United Kingdom--UK Norway |
| GeographicLocations_xml | – name: England – name: Scandinavian and Nordic Countries – name: Denmark – name: United Kingdom--UK – name: Sweden – name: Norway |
| GrantInformation | Early Diagnosis Policy Research Grant from Cancer Research UK (C7923/A18348). |
| GrantInformation_xml | – fundername: Cancer Research UK grantid: C7923/A18348 – fundername: Cancer Research UK grantid: 18525 – fundername: Cancer Research UK grantid: 18348 |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF 6I. AAFTH ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC ACNBI DF2 |
| ID | FETCH-LOGICAL-c745t-1d18719e092556814e206e7bf747bd18a7c55f3c6ac39825e8d66e430451b8973 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 112 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000454901700047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Tue Nov 04 16:47:33 EST 2025 Tue Nov 04 16:47:04 EST 2025 Tue Nov 04 01:47:31 EST 2025 Sun Nov 09 10:27:02 EST 2025 Tue Oct 07 05:19:18 EDT 2025 Mon Jul 21 05:35:29 EDT 2025 Tue Nov 18 22:29:04 EST 2025 Sat Nov 29 06:57:29 EST 2025 Fri Feb 23 02:18:58 EST 2024 Sun Feb 23 10:18:56 EST 2025 Tue Oct 14 19:35:44 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c745t-1d18719e092556814e206e7bf747bd18a7c55f3c6ac39825e8d66e430451b8973 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC6318222 |
| PMID | 30545752 |
| PQID | 2162985669 |
| PQPubID | 46089 |
| PageCount | 14 |
| ParticipantIDs | swepub_primary_oai_DiVA_org_uu_374440 swepub_primary_oai_DiVA_org_umu_155643 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6318222 proquest_miscellaneous_2157670959 proquest_journals_2162985669 pubmed_primary_30545752 crossref_primary_10_1016_S1470_2045_18_30646_6 crossref_citationtrail_10_1016_S1470_2045_18_30646_6 elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30646_6 elsevier_clinicalkeyesjournals_1_s2_0_S1470204518306466 elsevier_clinicalkey_doi_10_1016_S1470_2045_18_30646_6 |
| PublicationCentury | 2000 |
| PublicationDate | January 2019 2019 2019-01-00 20190101 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: January 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited Lancet Pub. Group |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Lancet Pub. Group |
| References | Schreuders, Ruco, Rabeneck (bib34) 2015; 64 Breugom, Swets, Bosset (bib50) 2015; 16 Chen, Cao, Chen (bib39) 2017; 39 (bib23) 2016 (bib33) 2016 Probst, Hussain, Andersen (bib58) 2012; 105 (bib66) 2018 Coleman, Forman, Bryant (bib3) 2011; 377 Allemani, Matsuda, Di Carlo (bib24) 2018; 391 Papamichael, Audisio, Glimelius (bib37) 2015; 26 (bib30) 2017 (bib60) 2017 Porter (bib65) 2016 Larsen, Njor, Ingeholm, Andersen (bib59) 2018; 155 Guren, Kørner, Pfeffer (bib8) 2015; 54 Richards (bib9) 2009; 101 Wilkins, Wickramasinghe, Bhatnagar (bib47) 2017 Royston, Sauerbrei (bib27) 2007; 7 Asli, Johannesen, Myklebust, Moller, Eriksen, Guren (bib51) 2017; 123 Påhlman, Cedermark, Bohe (bib13) 2008 van Gijn, van den Broek, Mroczkowski (bib43) 2012; 38 (bib32) 2017 Heald (bib10) 1979; 22 Morris, Sandin, Lambert (bib2) 2011; 60 Dimitriou, Griniatsos (bib12) 2015; 7 Brenner, Gefeller (bib25) 1997; 50 Hamaker, Schiphorst, Verweij, Pronk (bib40) 2014; 29 (bib64) 2012 Maringe, Walters, Rachet (bib5) 2013; 52 Bower, Crowther, Lambert (bib29) 2016; 16 (bib36) 2011 (bib1) 2015 Hohenberger, Weber, Matzel, Papadopoulos, Merkel (bib11) 2009; 11 Aronsson, Carlsson, Levin, Hager, Hultcrantz (bib61) 2017; 104 Yates, Chalmer, McKegney (bib44) 1980; 45 Tiselius, Gunnarsson, Smedh, Glimelius, Påhlman (bib48) 2013; 24 Peduzzi, Concato, Kemper, Holford, Feinstein (bib31) 1996; 49 Repetto, Fratino, Audisio (bib45) 2002; 20 Sorbye, Cvancarova, Qvortrup, Pfeiffer, Glimelius (bib54) 2013; 24 Kodeda, Johansson, Zar (bib7) 2015; 17 Walters, Benitez-Majano, Muller (bib4) 2015; 113 (bib57) 2000 van de Velde, Boelens, Borras (bib49) 2014; 50 Archampong, Borowski, Wille-Jorgensen, Iversen (bib56) 2012; 14 Ingeholm, Gögenur, Iversen (bib19) 2016; 8 Primrose, Falk, Finch-Jones (bib53) 2014; 15 Li, Abela, Moore (bib18) 2014; 38 Gatta, Capocaccia, Sant (bib55) 2000; 47 Corazziari, Quinn, Capocaccia (bib28) 2004; 40 (bib15) 2011 (bib21) 2000 Morris, Finan, Spencer (bib16) 2016; 28 (bib35) 2012 bib62 Benitez-Majano, Fowler, Maringe, Di Girolamo, Rachet (bib22) 2016; 115 Van Cutsem, Cervantes, Adam (bib52) 2016; 27 Moberger, Sköldberg, Birgisson (bib20) 2018 (bib26) 2015 Vallance, Fearnhead, Kuryba (bib63) 2018; 361 Stormark, Soreide, Soreide (bib41) 2016; 30 Stevenson (bib38) 2017; 104 Prince, Wu, Guo (bib46) 2015; 385 Glimelius, Myklebust, Lundqvist, Wibe, Guren (bib17) 2016; 121 Iversen, Green, Ingeholm, Osterlind, Gogenur (bib6) 2016; 55 (bib14) 2017 Iversen, Ingeholm, Gogenur, Laurberg (bib42) 2014; 21 Richards (10.1016/S1470-2045(18)30646-6_bib9) 2009; 101 Walters (10.1016/S1470-2045(18)30646-6_bib4) 2015; 113 Benitez-Majano (10.1016/S1470-2045(18)30646-6_bib22) 2016; 115 Iversen (10.1016/S1470-2045(18)30646-6_bib42) 2014; 21 Gatta (10.1016/S1470-2045(18)30646-6_bib55) 2000; 47 Brenner (10.1016/S1470-2045(18)30646-6_bib25) 1997; 50 Asli (10.1016/S1470-2045(18)30646-6_bib51) 2017; 123 Morris (10.1016/S1470-2045(18)30646-6_bib2) 2011; 60 Glimelius (10.1016/S1470-2045(18)30646-6_bib17) 2016; 121 Vallance (10.1016/S1470-2045(18)30646-6_bib63) 2018; 361 Stormark (10.1016/S1470-2045(18)30646-6_bib41) 2016; 30 Van Cutsem (10.1016/S1470-2045(18)30646-6_bib52) 2016; 27 Sorbye (10.1016/S1470-2045(18)30646-6_bib54) 2013; 24 (10.1016/S1470-2045(18)30646-6_bib60) 2017 Li (10.1016/S1470-2045(18)30646-6_bib18) 2014; 38 Wilkins (10.1016/S1470-2045(18)30646-6_bib47) 2017 Moberger (10.1016/S1470-2045(18)30646-6_bib20) 2018 (10.1016/S1470-2045(18)30646-6_bib21) 2000 Papamichael (10.1016/S1470-2045(18)30646-6_bib37) 2015; 26 (10.1016/S1470-2045(18)30646-6_bib15) 2011 (10.1016/S1470-2045(18)30646-6_bib35) 2012 van Gijn (10.1016/S1470-2045(18)30646-6_bib43) 2012; 38 Dimitriou (10.1016/S1470-2045(18)30646-6_bib12) 2015; 7 Peduzzi (10.1016/S1470-2045(18)30646-6_bib31) 1996; 49 Corazziari (10.1016/S1470-2045(18)30646-6_bib28) 2004; 40 Primrose (10.1016/S1470-2045(18)30646-6_bib53) 2014; 15 Porter (10.1016/S1470-2045(18)30646-6_bib65) 2016 Stevenson (10.1016/S1470-2045(18)30646-6_bib38) 2017; 104 Tiselius (10.1016/S1470-2045(18)30646-6_bib48) 2013; 24 (10.1016/S1470-2045(18)30646-6_bib36) 2011 Bower (10.1016/S1470-2045(18)30646-6_bib29) 2016; 16 Larsen (10.1016/S1470-2045(18)30646-6_bib59) 2018; 155 Archampong (10.1016/S1470-2045(18)30646-6_bib56) 2012; 14 Påhlman (10.1016/S1470-2045(18)30646-6_bib13) 2008 Ingeholm (10.1016/S1470-2045(18)30646-6_bib19) 2016; 8 Morris (10.1016/S1470-2045(18)30646-6_bib16) 2016; 28 Repetto (10.1016/S1470-2045(18)30646-6_bib45) 2002; 20 Breugom (10.1016/S1470-2045(18)30646-6_bib50) 2015; 16 Hamaker (10.1016/S1470-2045(18)30646-6_bib40) 2014; 29 Probst (10.1016/S1470-2045(18)30646-6_bib58) 2012; 105 Prince (10.1016/S1470-2045(18)30646-6_bib46) 2015; 385 Iversen (10.1016/S1470-2045(18)30646-6_bib6) 2016; 55 Hohenberger (10.1016/S1470-2045(18)30646-6_bib11) 2009; 11 Allemani (10.1016/S1470-2045(18)30646-6_bib24) 2018; 391 Kodeda (10.1016/S1470-2045(18)30646-6_bib7) 2015; 17 (10.1016/S1470-2045(18)30646-6_bib30) 2017 Maringe (10.1016/S1470-2045(18)30646-6_bib5) 2013; 52 Yates (10.1016/S1470-2045(18)30646-6_bib44) 1980; 45 Aronsson (10.1016/S1470-2045(18)30646-6_bib61) 2017; 104 van de Velde (10.1016/S1470-2045(18)30646-6_bib49) 2014; 50 Schreuders (10.1016/S1470-2045(18)30646-6_bib34) 2015; 64 Heald (10.1016/S1470-2045(18)30646-6_bib10) 1979; 22 Royston (10.1016/S1470-2045(18)30646-6_bib27) 2007; 7 Guren (10.1016/S1470-2045(18)30646-6_bib8) 2015; 54 (10.1016/S1470-2045(18)30646-6_bib57) 2000 Chen (10.1016/S1470-2045(18)30646-6_bib39) 2017; 39 Coleman (10.1016/S1470-2045(18)30646-6_bib3) 2011; 377 30545751 - Lancet Oncol. 2019 Jan;20(1):6-7. doi: 10.1016/S1470-2045(18)30679-X. |
| References_xml | – year: 2016 ident: bib33 article-title: National Care Programme—Colorectal Cancer – volume: 47 start-page: 533 year: 2000 end-page: 538 ident: bib55 article-title: Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study publication-title: Gut – volume: 50 start-page: 1 year: 2014 end-page: 34 ident: bib49 article-title: EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum publication-title: Eur J Cancer – volume: 104 start-page: 643 year: 2017 end-page: 645 ident: bib38 article-title: The future for laparoscopic rectal cancer surgery publication-title: Br J Surg – volume: 55 start-page: 10 year: 2016 end-page: 23 ident: bib6 article-title: Improved survival of colorectal cancer in Denmark during 2001–2012—the efforts of several national initiatives publication-title: Acta Oncol – volume: 8 start-page: 465 year: 2016 end-page: 468 ident: bib19 article-title: Danish Colorectal Cancer Group database publication-title: Clin Epidemiol – volume: 105 start-page: 65 year: 2012 end-page: 70 ident: bib58 article-title: Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians—a national Danish project publication-title: Health Policy – year: 2008 ident: bib13 article-title: Colorectal cancer, National care programme 2008 – year: 2011 ident: bib15 article-title: Colorectal cancer: diagnosis and management – year: 2016 ident: bib23 article-title: NHS Classifications OPCS-4 – year: 2012 ident: bib64 article-title: Health and Social Care Act 2012 – volume: 39 start-page: 1 year: 2017 end-page: 10 ident: bib39 article-title: Laparoscopic versus open surgery for rectal cancer: a meta-analysis of classic randomized controlled trials and high-quality nonrandomized studies in the last 5 years publication-title: Int J Surg – year: 2018 ident: bib20 article-title: Evaluation of the Swedish Colorectal Cancer Registry: an overview of completeness, timeliness, comparability and validity publication-title: Acta Oncol – volume: 30 start-page: 4853 year: 2016 end-page: 4864 ident: bib41 article-title: Nationwide implementation of laparoscopic surgery for colon cancer: short-term outcomes and long-term survival in a population-based cohort publication-title: Surg Endosc – volume: 28 start-page: 522 year: 2016 end-page: 531 ident: bib16 article-title: Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service publication-title: Clin Oncol (R Coll Radiol) – volume: 20 start-page: 494 year: 2002 end-page: 502 ident: bib45 article-title: Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study publication-title: J Clin Oncol – year: 2017 ident: bib14 article-title: National operational guidelines for diagnosis, treatment and follow-up of cancer of the colon and rectum – year: 2000 ident: bib57 article-title: The NHS Cancer Plan – year: 2012 ident: bib35 article-title: The impact of patient age on clinical decision-making in oncology – volume: 104 start-page: 1078 year: 2017 end-page: 1086 ident: bib61 article-title: Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer publication-title: Br J Surg – volume: 361 start-page: k1581 year: 2018 ident: bib63 article-title: Effect of public reporting of surgeons' outcomes on patient selection, “gaming,” and mortality in colorectal cancer surgery in England: population based cohort study publication-title: BMJ – volume: 29 start-page: 1231 year: 2014 end-page: 1236 ident: bib40 article-title: Improved survival for older patients undergoing surgery for colorectal cancer between 2008 and 2011 publication-title: Int J Colorectal Dis – year: 2015 ident: bib26 article-title: Cancer Survival Group UK life tables – year: 2017 ident: bib30 article-title: Stata Statistical Software: release 15 – year: 2015 ident: bib1 article-title: GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 – volume: 11 start-page: 354 year: 2009 end-page: 364 ident: bib11 article-title: Standardized surgery for colonic cancer: complete mesocolic excision and central ligation—technical notes and outcome publication-title: Colorectal Dis – volume: 24 start-page: 2354 year: 2013 end-page: 2360 ident: bib54 article-title: Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer publication-title: Ann Oncol – volume: 14 year: 2012 ident: bib56 article-title: Workload and surgeon's specialty for outcome after colorectal cancer surgery publication-title: Cochrane Database Syst Rev – volume: 391 start-page: 1023 year: 2018 end-page: 1075 ident: bib24 article-title: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries publication-title: Lancet – volume: 40 start-page: 2307 year: 2004 end-page: 2316 ident: bib28 article-title: Standard cancer patient population for age standardising survival ratios publication-title: Eur J Cancer – volume: 385 start-page: 549 year: 2015 end-page: 562 ident: bib46 article-title: The burden of disease in older people and implications for health policy and practice publication-title: Lancet – volume: 64 start-page: 1637 year: 2015 end-page: 1649 ident: bib34 article-title: Colorectal cancer screening: a global overview of existing programmes publication-title: Gut – year: 2017 ident: bib47 article-title: European cardiovascular disease statistics 2017 – volume: 115 start-page: 391 year: 2016 end-page: 400 ident: bib22 article-title: Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England publication-title: Br J Cancer – volume: 54 start-page: 1714 year: 2015 end-page: 1722 ident: bib8 article-title: Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010 publication-title: Acta Oncol – volume: 24 start-page: 160 year: 2013 end-page: 165 ident: bib48 article-title: Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study publication-title: Ann Oncol – volume: 16 start-page: 200 year: 2015 end-page: 207 ident: bib50 article-title: Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data publication-title: Lancet Oncol – volume: 38 start-page: 467 year: 2012 end-page: 471 ident: bib43 article-title: The EURECCA project: data items scored by European colorectal cancer audit registries publication-title: Eur J Surg Oncol – volume: 60 start-page: 1087 year: 2011 end-page: 1093 ident: bib2 article-title: A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004 publication-title: Gut – volume: 50 start-page: 211 year: 1997 end-page: 216 ident: bib25 article-title: Deriving more up-to-date estimates of long-term patient survival publication-title: J Clin Epidemiol – year: 2011 ident: bib36 article-title: Major surgical resections—England, 2004–2006 – year: 2017 ident: bib32 article-title: Danish Colorectal Cancer Group's current guidelines – volume: 7 start-page: 45 year: 2007 ident: bib27 article-title: Multivariable modeling with cubic regression splines: a principled approach publication-title: Stata J – volume: 49 start-page: 1373 year: 1996 end-page: 1379 ident: bib31 article-title: A simulation study of the number of events per variable in logistic regression analysis publication-title: J Clin Epidemiol – volume: 377 start-page: 127 year: 2011 end-page: 138 ident: bib3 article-title: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data publication-title: Lancet – volume: 7 start-page: 383 year: 2015 end-page: 388 ident: bib12 article-title: Complete mesocolic excision: techniques and outcomes publication-title: World J Gastrointest Oncol – year: 2016 ident: bib65 article-title: NHS funding and efficiency savings – volume: 113 start-page: 848 year: 2015 end-page: 860 ident: bib4 article-title: Is England closing the international gap in cancer survival? publication-title: Br J Cancer – volume: 155 start-page: 99 year: 2018 end-page: 106 ident: bib59 article-title: Effectiveness of colorectal cancer screening in detecting earlier-stage disease— a nationwide cohort study in Denmark publication-title: Gastroenterology – volume: 21 start-page: 2267 year: 2014 end-page: 2273 ident: bib42 article-title: Major reduction in 30-day mortality after elective colorectal cancer surgery: a nationwide population-based study in Denmark 2001–2011 publication-title: Ann Surg Oncol – volume: 15 start-page: 601 year: 2014 end-page: 611 ident: bib53 article-title: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial publication-title: Lancet Oncol – year: 2018 ident: bib66 article-title: Patients in limbo as cancer waiting time targets missed for two years running – volume: 16 start-page: 989 year: 2016 end-page: 1012 ident: bib29 article-title: A command for fitting flexible parametric survival models on the log-hazard scale publication-title: Stata J – volume: 45 start-page: 2220 year: 1980 end-page: 2224 ident: bib44 article-title: Evaluation of patients with advanced cancer using the Karnofsky performance status publication-title: Cancer – volume: 26 start-page: 463 year: 2015 end-page: 476 ident: bib37 article-title: Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013 publication-title: Ann Oncol – volume: 101 start-page: S125 year: 2009 end-page: S129 ident: bib9 article-title: The size of the prize for earlier diagnosis of cancer in England publication-title: Br J Cancer – volume: 27 start-page: 1386 year: 2016 end-page: 1422 ident: bib52 article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer publication-title: Ann Oncol – volume: 123 start-page: 446 year: 2017 end-page: 453 ident: bib51 article-title: Preoperative chemoradiotherapy for rectal cancer and impact on outcomes—a population-based study publication-title: Radiother Oncol – volume: 22 start-page: 277 year: 1979 end-page: 281 ident: bib10 article-title: A new approach to rectal cancer publication-title: Br J Hosp Med – volume: 17 start-page: O168 year: 2015 end-page: O179 ident: bib7 article-title: Time trends, improvements and national auditing of rectal cancer management over an 18-year period publication-title: Colorectal Dis – volume: 38 start-page: 314 year: 2014 end-page: 320 ident: bib18 article-title: Control of data quality for population-based cancer survival analysis publication-title: Cancer Epidemiol – year: 2017 ident: bib60 article-title: National screening programme against bowel cancer—status and recommendations – ident: bib62 article-title: Bowel scope screening – year: 2000 ident: bib21 publication-title: International Classification of Diseases for Oncology (ICD-O) – volume: 121 start-page: 357 year: 2016 end-page: 363 ident: bib17 article-title: Two countries—two treatment strategies for rectal cancer publication-title: Radiother Oncol – volume: 52 start-page: 919 year: 2013 end-page: 932 ident: bib5 article-title: Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000–7 publication-title: Acta Oncol – volume: 27 start-page: 1386 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib52 article-title: ESMO consensus guidelines for the management of patients with metastatic colorectal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdw235 – volume: 64 start-page: 1637 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib34 article-title: Colorectal cancer screening: a global overview of existing programmes publication-title: Gut doi: 10.1136/gutjnl-2014-309086 – volume: 115 start-page: 391 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib22 article-title: Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England publication-title: Br J Cancer doi: 10.1038/bjc.2016.177 – volume: 29 start-page: 1231 year: 2014 ident: 10.1016/S1470-2045(18)30646-6_bib40 article-title: Improved survival for older patients undergoing surgery for colorectal cancer between 2008 and 2011 publication-title: Int J Colorectal Dis doi: 10.1007/s00384-014-1959-y – volume: 54 start-page: 1714 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib8 article-title: Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993–2010 publication-title: Acta Oncol doi: 10.3109/0284186X.2015.1034876 – volume: 26 start-page: 463 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib37 article-title: Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013 publication-title: Ann Oncol doi: 10.1093/annonc/mdu253 – year: 2017 ident: 10.1016/S1470-2045(18)30646-6_bib60 – volume: 8 start-page: 465 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib19 article-title: Danish Colorectal Cancer Group database publication-title: Clin Epidemiol doi: 10.2147/CLEP.S99481 – year: 2017 ident: 10.1016/S1470-2045(18)30646-6_bib30 – volume: 113 start-page: 848 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib4 article-title: Is England closing the international gap in cancer survival? publication-title: Br J Cancer doi: 10.1038/bjc.2015.265 – volume: 40 start-page: 2307 year: 2004 ident: 10.1016/S1470-2045(18)30646-6_bib28 article-title: Standard cancer patient population for age standardising survival ratios publication-title: Eur J Cancer doi: 10.1016/j.ejca.2004.07.002 – volume: 24 start-page: 2354 year: 2013 ident: 10.1016/S1470-2045(18)30646-6_bib54 article-title: Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer publication-title: Ann Oncol doi: 10.1093/annonc/mdt197 – volume: 60 start-page: 1087 year: 2011 ident: 10.1016/S1470-2045(18)30646-6_bib2 article-title: A population-based comparison of the survival of patients with colorectal cancer in England, Norway and Sweden between 1996 and 2004 publication-title: Gut doi: 10.1136/gut.2010.229575 – volume: 39 start-page: 1 year: 2017 ident: 10.1016/S1470-2045(18)30646-6_bib39 article-title: Laparoscopic versus open surgery for rectal cancer: a meta-analysis of classic randomized controlled trials and high-quality nonrandomized studies in the last 5 years publication-title: Int J Surg doi: 10.1016/j.ijsu.2016.12.123 – volume: 55 start-page: 10 issue: suppl 2 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib6 article-title: Improved survival of colorectal cancer in Denmark during 2001–2012—the efforts of several national initiatives publication-title: Acta Oncol doi: 10.3109/0284186X.2015.1131331 – volume: 17 start-page: O168 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib7 article-title: Time trends, improvements and national auditing of rectal cancer management over an 18-year period publication-title: Colorectal Dis doi: 10.1111/codi.13060 – volume: 7 start-page: 45 year: 2007 ident: 10.1016/S1470-2045(18)30646-6_bib27 article-title: Multivariable modeling with cubic regression splines: a principled approach publication-title: Stata J doi: 10.1177/1536867X0700700103 – year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib65 – volume: 28 start-page: 522 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib16 article-title: Wide variation in the use of radiotherapy in the management of surgically treated rectal cancer across the English National Health Service publication-title: Clin Oncol (R Coll Radiol) doi: 10.1016/j.clon.2016.02.002 – volume: 22 start-page: 277 year: 1979 ident: 10.1016/S1470-2045(18)30646-6_bib10 article-title: A new approach to rectal cancer publication-title: Br J Hosp Med – volume: 104 start-page: 643 year: 2017 ident: 10.1016/S1470-2045(18)30646-6_bib38 article-title: The future for laparoscopic rectal cancer surgery publication-title: Br J Surg doi: 10.1002/bjs.10503 – volume: 15 start-page: 601 year: 2014 ident: 10.1016/S1470-2045(18)30646-6_bib53 article-title: Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70105-6 – volume: 105 start-page: 65 year: 2012 ident: 10.1016/S1470-2045(18)30646-6_bib58 article-title: Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians—a national Danish project publication-title: Health Policy doi: 10.1016/j.healthpol.2011.11.001 – volume: 123 start-page: 446 year: 2017 ident: 10.1016/S1470-2045(18)30646-6_bib51 article-title: Preoperative chemoradiotherapy for rectal cancer and impact on outcomes—a population-based study publication-title: Radiother Oncol doi: 10.1016/j.radonc.2017.04.012 – volume: 385 start-page: 549 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib46 article-title: The burden of disease in older people and implications for health policy and practice publication-title: Lancet doi: 10.1016/S0140-6736(14)61347-7 – volume: 7 start-page: 383 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib12 article-title: Complete mesocolic excision: techniques and outcomes publication-title: World J Gastrointest Oncol doi: 10.4251/wjgo.v7.i12.383 – volume: 21 start-page: 2267 year: 2014 ident: 10.1016/S1470-2045(18)30646-6_bib42 article-title: Major reduction in 30-day mortality after elective colorectal cancer surgery: a nationwide population-based study in Denmark 2001–2011 publication-title: Ann Surg Oncol doi: 10.1245/s10434-014-3596-7 – year: 2011 ident: 10.1016/S1470-2045(18)30646-6_bib15 – year: 2000 ident: 10.1016/S1470-2045(18)30646-6_bib21 – volume: 121 start-page: 357 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib17 article-title: Two countries—two treatment strategies for rectal cancer publication-title: Radiother Oncol doi: 10.1016/j.radonc.2016.11.010 – volume: 14 year: 2012 ident: 10.1016/S1470-2045(18)30646-6_bib56 article-title: Workload and surgeon's specialty for outcome after colorectal cancer surgery publication-title: Cochrane Database Syst Rev – volume: 47 start-page: 533 year: 2000 ident: 10.1016/S1470-2045(18)30646-6_bib55 article-title: Understanding variations in survival for colorectal cancer in Europe: a EUROCARE high resolution study publication-title: Gut doi: 10.1136/gut.47.4.533 – volume: 38 start-page: 314 year: 2014 ident: 10.1016/S1470-2045(18)30646-6_bib18 article-title: Control of data quality for population-based cancer survival analysis publication-title: Cancer Epidemiol doi: 10.1016/j.canep.2014.02.013 – volume: 20 start-page: 494 year: 2002 ident: 10.1016/S1470-2045(18)30646-6_bib45 article-title: Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study publication-title: J Clin Oncol doi: 10.1200/JCO.2002.20.2.494 – volume: 49 start-page: 1373 year: 1996 ident: 10.1016/S1470-2045(18)30646-6_bib31 article-title: A simulation study of the number of events per variable in logistic regression analysis publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(96)00236-3 – volume: 155 start-page: 99 year: 2018 ident: 10.1016/S1470-2045(18)30646-6_bib59 article-title: Effectiveness of colorectal cancer screening in detecting earlier-stage disease— a nationwide cohort study in Denmark publication-title: Gastroenterology doi: 10.1053/j.gastro.2018.03.062 – volume: 38 start-page: 467 year: 2012 ident: 10.1016/S1470-2045(18)30646-6_bib43 article-title: The EURECCA project: data items scored by European colorectal cancer audit registries publication-title: Eur J Surg Oncol doi: 10.1016/j.ejso.2012.01.005 – volume: 377 start-page: 127 year: 2011 ident: 10.1016/S1470-2045(18)30646-6_bib3 article-title: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data publication-title: Lancet doi: 10.1016/S0140-6736(10)62231-3 – year: 2000 ident: 10.1016/S1470-2045(18)30646-6_bib57 – volume: 50 start-page: 211 year: 1997 ident: 10.1016/S1470-2045(18)30646-6_bib25 article-title: Deriving more up-to-date estimates of long-term patient survival publication-title: J Clin Epidemiol doi: 10.1016/S0895-4356(97)00280-1 – volume: 45 start-page: 2220 year: 1980 ident: 10.1016/S1470-2045(18)30646-6_bib44 article-title: Evaluation of patients with advanced cancer using the Karnofsky performance status publication-title: Cancer doi: 10.1002/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q – volume: 361 start-page: k1581 year: 2018 ident: 10.1016/S1470-2045(18)30646-6_bib63 article-title: Effect of public reporting of surgeons' outcomes on patient selection, “gaming,” and mortality in colorectal cancer surgery in England: population based cohort study publication-title: BMJ doi: 10.1136/bmj.k1581 – year: 2017 ident: 10.1016/S1470-2045(18)30646-6_bib47 – volume: 104 start-page: 1078 year: 2017 ident: 10.1016/S1470-2045(18)30646-6_bib61 article-title: Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer publication-title: Br J Surg doi: 10.1002/bjs.10536 – year: 2018 ident: 10.1016/S1470-2045(18)30646-6_bib20 article-title: Evaluation of the Swedish Colorectal Cancer Registry: an overview of completeness, timeliness, comparability and validity publication-title: Acta Oncol doi: 10.1080/0284186X.2018.1529425 – year: 2008 ident: 10.1016/S1470-2045(18)30646-6_bib13 – volume: 16 start-page: 200 year: 2015 ident: 10.1016/S1470-2045(18)30646-6_bib50 article-title: Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71199-4 – volume: 16 start-page: 989 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib29 article-title: A command for fitting flexible parametric survival models on the log-hazard scale publication-title: Stata J doi: 10.1177/1536867X1601600410 – volume: 30 start-page: 4853 year: 2016 ident: 10.1016/S1470-2045(18)30646-6_bib41 article-title: Nationwide implementation of laparoscopic surgery for colon cancer: short-term outcomes and long-term survival in a population-based cohort publication-title: Surg Endosc doi: 10.1007/s00464-016-4819-8 – year: 2012 ident: 10.1016/S1470-2045(18)30646-6_bib35 – volume: 50 start-page: 1 year: 2014 ident: 10.1016/S1470-2045(18)30646-6_bib49 article-title: EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.06.048 – volume: 11 start-page: 354 year: 2009 ident: 10.1016/S1470-2045(18)30646-6_bib11 article-title: Standardized surgery for colonic cancer: complete mesocolic excision and central ligation—technical notes and outcome publication-title: Colorectal Dis doi: 10.1111/j.1463-1318.2008.01735.x – volume: 24 start-page: 160 year: 2013 ident: 10.1016/S1470-2045(18)30646-6_bib48 article-title: Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study publication-title: Ann Oncol doi: 10.1093/annonc/mds278 – year: 2011 ident: 10.1016/S1470-2045(18)30646-6_bib36 – volume: 391 start-page: 1023 year: 2018 ident: 10.1016/S1470-2045(18)30646-6_bib24 article-title: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries publication-title: Lancet doi: 10.1016/S0140-6736(17)33326-3 – volume: 101 start-page: S125 issue: suppl 2 year: 2009 ident: 10.1016/S1470-2045(18)30646-6_bib9 article-title: The size of the prize for earlier diagnosis of cancer in England publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605402 – volume: 52 start-page: 919 year: 2013 ident: 10.1016/S1470-2045(18)30646-6_bib5 article-title: Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000–7 publication-title: Acta Oncol doi: 10.3109/0284186X.2013.764008 – reference: 30545751 - Lancet Oncol. 2019 Jan;20(1):6-7. doi: 10.1016/S1470-2045(18)30679-X. |
| SSID | ssj0017105 |
| Score | 2.5888193 |
| Snippet | Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from national... SummaryBackgroundSurvival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from... Summary Background Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data... Background Survival from colorectal cancer has been shown to be lower in Denmark and England than in comparable high-income countries. We used data from... |
| SourceID | swepub pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 74 |
| SubjectTerms | Adenocarcinoma Adenocarcinoma - mortality Adenocarcinoma - pathology Adenocarcinoma - surgery adjuvant chemotherapy Adolescent Adult Age Age Factors Aged Aged, 80 and over Cancer therapies Colectomy - mortality Colectomy - standards Colectomy - statistics & numerical data Colon cancer Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery complete mesocolic excision diagnosis England - epidemiology Female Health risk assessment Hematology, Oncology, and Palliative Medicine Humans Invasiveness Male management metaanalysis Middle Aged Multivariate Analysis older patients Patients Population Population studies Population-based studies radiotherapy rectal-cancer Rectum Registries Scandinavian and Nordic Countries - epidemiology Surgery Survival Survival Analysis Tumors Young Adult |
| Title | Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204518306466 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204518306466 https://dx.doi.org/10.1016/S1470-2045(18)30646-6 https://www.ncbi.nlm.nih.gov/pubmed/30545752 https://www.proquest.com/docview/2162985669 https://www.proquest.com/docview/2157670959 https://pubmed.ncbi.nlm.nih.gov/PMC6318222 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-155643 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-374440 |
| Volume | 20 |
| WOSCitedRecordID | wos000454901700047&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251007 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgQ4gXvj8CYzISIJAaFjeuHfOCxj7EA1TTClXfLMdxtgqWlqRh8N9zl6SeqsGGhBRZSu1fIteXu5_t8x0hzw1TmbHchilzKuR5Dp8URxeojDGhRJ7GzQm58Uc5HCaTiTroFtyqzq1yqRMbRZ3NLK6Rb_WZ6KsEyId6N_8eYtYo3F3tUmhcJesMbTfIszwc-10E2bowMi6jEMOun53g2Rr5H1-x5DXScBGKv9mm89zzvAvlSqDRxjjt3_rfbt0mNztaSrdbObpDrrjiLrn-qdt4v0d-juqy0ZHUe6ZTU2S0qkHVgLBSPKZCMQI2alC4tyhNJZ0WdNcVJ6b82qNdvpAeHc7KU_Or1zxgdOpA872lhs59KrEQTSs8GyPf3idf9vc-73wIu6QNoZV8sMBBhjmYcpFqg5tx14-Ek2kO85YU6oy0g0EeW2FsrGB66pJMCMdxw5aliZLxA7JWzAr3iFAnuYiMyeCSPFUAjXNuo9gxkwmgJQHhy-HStotojok1vmnvuoajrHGUNUt0M8paBOSNh83bkB6XAcRSFvTyvCpoWA1G5zKg_BPQVZ2eqDTTVV9HLRrBoGARCsjEIzsq1FKcf3npxlLStH_PmZgF5JmvBk2C20OmcLMa28DcU-K6cEAettLt_x-wChyIfR96tCL3vgFGKV-tKabHTbRyAVYDSGhAXrZfyApkdzre1rPySNcntQZqC_w4IC8ubFjrWHLOo8cX9_MJuQHcVrWrZRtkbVHW7im5Zn8splW52egJLCeyKRMokx22Sdbf7w0PDn8DcURwFg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELfGQMAL3x-BAUZiCKSGxYlrx0gITZRp07oKqWPqm3ESBypYWtKGsn-Kv5G7fE3VYONlD0h9Se1z4uQ-fmef7wh5ZphKTMxjN2JWuTxNQaQ4hkAljAkl0igoT8gd9OVgEI5G6sMK-dWchcGwykYnloo6mcS4Rr7hM-GrEMCHejv97mLVKNxdbUpoVGyxa48W4LLN3uz04Puu-_7W-_13225dVcCNJe_O8SnASVDWU1X2LW59T1gZpQCsI2gzMu520yAWJg4U-E82TISwHHcUWRQqGcC4F8hF0OMSQ8jkqHXwmKxCJhmXnotp3o9PDG0M2z9fsPAlwn7hir_ZwpNY92TI5lJi09IYbl3_317jDXKtht10s5KTm2TFZrfI5b06sOA2-Tks8tIG0DbynposobMCVCkII8VjOBQzfKOFgOsYpSWn44z2bHZo8q8dWtdD6dDBJF-Yo045wHBhQbO_poZO21JpLkIHGBsz-94hH89l3nfJajbJ7H1CreTCMyaBn-SRAtIg5bEXWGYSAbDLIbxhDx3XGduxcMg33YbmIVdp5CrNQl1ylRYOedWSTauUJWcRiIb3dHMeFyyIBqN6FqH8E6Gd1Xpwppme-dqrqJEYDAiSAmXYUtZQr4Jw_3LTtYazdXufY7Z2yNO2GTQlbn-ZzE4K7AO-tcR1b4fcq6SpfT9g9Tg4Lj7MaEnO2g6YhX25JRt_KbOxC7CKALId8rySyCWS3vhgU0_yz7o4LDRAd8D_Dlk_tWOhA8k59x6cPs8n5Mr2_l5f93cGuw_JVcDxqloZXCOr87ywj8il-Md8PMsflzqKkk_nLc2_AWLexVc |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELfGQBMvfH8EBhiJIZAaGieuHSMhNFEqpo1qUmHqm3ESBypYWtKGsn-Nv467fE3VYONlD0h9Se1z4uQ-fmef7wh5YphKTMxjN2JWuTxNQaQ4hkAljAkl0igoT8gd7MnhMByP1f4a-dWchcGwykYnloo6mca4Rt71mfBVCOBDddM6LGK_P3g9--5iBSncaW3KaVQssmuPluC-zV_t9OFbb_n-4O2HN-_cusKAG0veW-ATgcOgrKeqTFzc-p6wMkoBZEfQZmTc66VBLEwcKPClbJgIYTnuLrIoVDKAcS-QizIIJJaNkOPW2WOyCp9kXHoupnw_Pj3UHbV_PmPhc3QBhCv-ZhdP4t6T4ZsrSU5Lwzi4-j-_0mvkSg3H6XYlP9fJms1ukI33dcDBTfJzVOSlbaBtRD41WULnBahYEFKKx3MoZv5GywHXMUpRTicZ7dvs0ORfO7Suk9Khw2m-NEedcoDR0oLGf0kNnbUl1FyEFDA2Zvy9RT6ey7xvk_Vsmtm7hFrJhWdMAj_JIwWkQcpjL7DMJALgmEN4wyo6rjO5Y0GRb7oN2UMO08hhmoW65DAtHPKiJZtVqUzOIhANH-rmnC5YFg3G9ixC-SdCO6_141wzPfe1V1EjMRgWJAXKsKWsIWAF7f7lppsNl-v2Pscs7pDHbTNoUNwWM5mdFtgHfG6J6-EOuVNJVvt-wBpycGh8mNGKzLUdMDv7aks2-VJmaRdgLQF8O-RpJZ0rJP3Jwbae5p91cVhogPTgFzhk69SOhQ4k59y7d_o8H5ENEGK9tzPcvU8uA7xX1YLhJllf5IV9QC7FPxaTef6wVFeUfDpvYf4NosfOCw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Surgical+treatment+and+survival+from+colorectal+cancer+in+Denmark%2C+England%2C+Norway%2C+and+Sweden%3A+a+population-based+study&rft.jtitle=The+lancet+oncology&rft.au=Benitez+Majano%2C+Sara%2C+MSc&rft.au=Di+Girolamo%2C+Chiara%2C+MSc&rft.au=Rachet%2C+Bernard%2C+Prof&rft.au=Maringe%2C+Camille%2C+MSc&rft.date=2019&rft.issn=1470-2045&rft.volume=20&rft.issue=1&rft.spage=74&rft.epage=87&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930646-6&rft.externalDBID=ECK1-s2.0-S1470204518306466&rft.externalDocID=1_s2_0_S1470204518306466 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204518X00138%2Fcov150h.gif |